Byoung-Gie Kim

List of Publications by Year
in descending order

164 papers	6,461 citations	201674 27 h-index	74163 75 g-index
166 all docs	166 docs citations	166 times ranked	7925 citing authors

#	Article	IF	Citations
1	Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. New England Journal of Medicine, 2018, 379, 2495-2505.	27.0	1,854
2	Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncology, The, 2017, 18, 1274-1284.	10.7	1,376
3	Bevacizumab and paclitaxelâ€“carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncology, The, 2017, 18, 779-791.	10.7	460
4	Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology, The, 2021, 22, 1721-1731.	10.7	172
5	Single-port-access laparoscopic-assisted vaginal hysterectomy versus conventional laparoscopic-assisted vaginal hysterectomy: a comparison of perioperative outcomes. Surgical Endoscopy and Other Interventional Techniques, 2010, 24, 2248-2252.	2.4	121
6	Randomized Phase III Trial of Irinotecan Plus Cisplatin Compared With Paclitaxel Plus Carboplatin As First-Line Chemotherapy for Ovarian Clear Cell Carcinoma: JGOG3017/GCIG Trial. Journal of Clinical Oncology, 2016, 34, 2881-2887.	1.6	114
7	Pembrolizumab plus GX-188E therapeutic DNA vaccine in patients with HPV-16-positive or HPV-18-positive advanced cervical cancer: interim results of a single-arm, phase 2 trial. Lancet Oncology, The, 2020, 21, 1653-1660.	10.7	89
8	The prognostic significance of the SUVmax (maximum standardized uptake value for F-18) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 467 Td results. Gynecologic Oncology, 2009, 115, 65-68.	1.4	78
9	Appraising the role of previously reported risk factors in epithelial ovarian cancer risk: A Mendelian randomization analysis. PLoS Medicine, 2019, 16, e1002893.	8.4	78
10	Efficacy of Maintenance Olaparib for Patients With Newly Diagnosed Advanced Ovarian Cancer With a BRCA Mutation: Subgroup Analysis Findings From the SOLO1 Trial. Journal of Clinical Oncology, 2020, 38, 3528-3537.	1.6	64
11	Prognostic factors and outcomes in endometrial stromal sarcoma with the 2009 FIGO staging system: A multicenter review of 114 cases. Gynecologic Oncology, 2014, 132, 70-75.	1.4	63
12	An Open-Label, Randomized, Parallel, Phase II Trial to Evaluate the Efficacy and Safety of a Cremophor-Free Polymeric Micelle Formulation of Paclitaxel as First-Line Treatment for Ovarian Cancer: A Korean Gynecologic Oncology Group Study (KGOG-3021). Cancer Research and Treatment, 2018, 50, 195-203.	3.0	59
13	Patient-Derived Xenograft Models of Epithelial Ovarian Cancer for Preclinical Studies. Cancer Research and Treatment, 2017, 49, 915-926.	3.0	58
14	Sphingosine kinase 1 is a reliable prognostic factor and a novel therapeutic target for uterine cervical cancer. Oncotarget, 2015, 6, 26746-26756.	1.8	55
15	The Effect of Breastfeeding Duration and Parity on the Risk of Epithelial Ovarian Cancer: A Systematic Review and Meta-analysis. Journal of Preventive Medicine and Public Health, 2016, 49, 349-366.	1.9	54
16	HER2 as a novel therapeutic target for cervical cancer. Oncotarget, 2015, 6, 36219-36230.	1.8	51
17	Proton pump inhibitors enhance the effects of cytotoxic agents in chemoresistant epithelial ovarian carcinoma. Oncotarget, 2015, 6, 35040-35050.	1.8	48
18	Survival analysis of revised 2013 FIGO staging classification of epithelial ovarian cancer and comparison with previous FIGO staging classification. Obstetrics and Gynecology Science, 2015, 58, 124.	1.6	45

#	Article	IF	Citations
19	Expression of fibroblast growth factor receptor family members is associated with prognosis in early stage cervical cancer patients. Journal of Translational Medicine, 2016, 14, 124.	4.4	40
20	Patient-centred outcomes and effect of disease progression on health status in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation receiving maintenance olaparib or placebo (SOLO1): a randomised, phase 3 trial. Lancet Oncology, The, 2021, 22, 632-642.	10.7	40
21	Preoperative assessment of lymph node metastasis in endometrial cancer: A Korean Gynecologic Oncology Group study. Cancer, 2017, 123, 263-272.	4.1	38
22	Prediction of survival outcomes in patients with epithelial ovarian cancer using machine learning methods. Journal of Gynecologic Oncology, 2019, 30, e65.	2.2	38
23	The anti-cancer effects of itraconazole in epithelial ovarian cancer. Scientific Reports, 2017, 7, 6552.	3.3	37
24	c-MET as a Potential Therapeutic Target in Ovarian Clear Cell Carcinoma. Scientific Reports, 2016, 6, 38502.	3.3	34
25	Perioperative administration of propranolol to women undergoing ovarian cancer surgery: A pilot study. Obstetrics and Gynecology Science, 2017, 60, 170.	1.6	33
26	Surgical Outcomes of a New Approach to Laparoscopic Myomectomy: Single-Port and Modified Suture Technique. Journal of Minimally Invasive Gynecology, 2014, 21, 580-585.	0.6	31
27	Interval between secondary cytoreductive surgery and adjuvant chemotherapy is not associated with survivals in patients with recurrent ovarian cancer. Journal of Ovarian Research, 2020, 13, 1.	3.0	31
28	Dual targeting of angiotensin receptors (AGTR1 and AGTR2) in epithelial ovarian carcinoma. Gynecologic Oncology, 2014, 135, 108-117.	1.4	29
29	Clinical outcomes of patients with clear cell and endometrioid ovarian cancer arising from endometriosis. Journal of Gynecologic Oncology, 2018, 29, e18.	2.2	29
30	Papillary serous carcinoma in ovaries of normal size: A clinicopathologic study of 20 cases and comparison with extraovarian peritoneal papillary serous carcinoma. Gynecologic Oncology, 2007, 105, 762-768.	1.4	28
31	Somatic Copy Number Alterations Associated with Japanese or Endometriosis in Ovarian Clear Cell Adenocarcinoma. PLoS ONE, 2015, 10, e0116977.	2.5	28
32	Clinical outcomes in patients treated with radiotherapy after surgery for cervical cancer. Radiation Oncology Journal, 2017, 35, 39-47.	1.5	28
33	Genome-wide association studies identify susceptibility loci for epithelial ovarian cancer in east Asian women. Gynecologic Oncology, 2019, 153, 343-355.	1.4	28
34	Prognostic value of pretreatment hemoglobin level in patients with early cervical cancer. Obstetrics and Gynecology Science, 2014, 57, 28.	1.6	27
35	Linalool-Incorporated Nanoparticles as a Novel Anticancer Agent for Epithelial Ovarian Carcinoma. Molecular Cancer Therapeutics, 2016, 15, 618-627.	4.1	27
36	Targeted Inhibition of FAK, PYK2 and BCL-XL Synergistically Enhances Apoptosis in Ovarian Clear Cell Carcinoma Cell Lines. PLoS ONE, 2014, 9, e88587.	2.5	25

#	Article	IF	Citations
37	Robotic Single-port Hysterectomy, Adnexectomy, and Lymphadenectomy in Endometrial Cancer. Journal of Minimally Invasive Gynecology, 2015, 22, 322.	0.6	24
38	Proton Pump Inhibition Enhances the Cytotoxicity of Paclitaxel in Cervical Cancer. Cancer Research and Treatment, 2017, 49, 595-606.	3.0	24
39	Survival impact based on the thoroughness of pelvic lymphadenectomy in intermediate- or high-risk groups of endometrioid-type endometrial cancer: A multi-center retrospective cohort analysis. Gynecologic Oncology, 2016, 141, 440-446.	1.4	23
40	Polygenic risk modeling for prediction of epithelial ovarian cancer risk. European Journal of Human Genetics, 2022, 30, 349-362.	2.8	23
41	Pulmonary metastasectomy in uterine malignancy: outcomes and prognostic factors. Journal of Gynecologic Oncology, 2015, 26, 270.	2.2	22
42	Minimally invasive compared with open surgery in patients with borderline ovarian tumors. Gynecologic Oncology, 2017, 145, 508-512.	1.4	21
43	Biomarker-guided targeted therapy in platinum-resistant ovarian cancer (AMBITION; KGOG 3045): a multicentre, open-label, five-arm, uncontrolled, umbrella trial. Journal of Gynecologic Oncology, 2022, 33, .	2.2	21
44	The clinical value of surgeons' efforts of preventing intraoperative tumor rupture in stage I clear cell carcinoma of the ovary: A Korean multicenter study. Gynecologic Oncology, 2015, 137, 412-417.	1.4	20
45	Impact of lymphadenectomy on survival after recurrence in patients with advanced ovarian cancer without suspected lymph node metastasis. Gynecologic Oncology, 2016, 143, 252-257.	1.4	20
46	Update on rare epithelial ovarian cancers: based on the Rare Ovarian Tumors Young Investigator Conference. Journal of Gynecologic Oncology, 2017, 28, e54.	2.2	20
47	Primary ovarian choriocarcinoma mimicking ectopic pregnancy. Obstetrics and Gynecology Science, 2014, 57, 330.	1.6	19
48	Surgical outcome prediction in patients with advanced ovarian cancer using computed tomography scans and intraoperative findings. Taiwanese Journal of Obstetrics and Gynecology, 2014, 53, 343-347.	1.3	19
49	Population attributable risks of modifiable reproductive factors for breast and ovarian cancers in Korea. BMC Cancer, 2016, 16, 5.	2.6	19
50	Clinical outcomes of primary surgical treatment for acquired vulvar lymphangioma circumscriptum. Archives of Gynecology and Obstetrics, 2016, 293, 157-162.	1.7	18
51	Extrauterine epithelioid trophoblastic tumor in hysterectomized woman. Obstetrics and Gynecology Science, 2017, 60, 124.	1.6	18
52	Cosmesis and body image after singleâ€port access surgery for gynaecologic disease. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2012, 52, 465-469.	1.0	17
53	Safe Criteria for Less Radical Trachelectomy in Patients with Early-Stage Cervical Cancer: A Multicenter Clinicopathologic Study. Annals of Surgical Oncology, 2012, 19, 1973-1979.	1.5	17
54	Outcomes of laparoscopic fertility-sparing surgery in clinically early-stage epithelial ovarian cancer. Journal of Gynecologic Oncology, 2016, 27, e20.	2.2	17

#	Article	IF	Citations
55	Uterine Fibroids: Correlation of T2 Signal Intensity with Semiquantitative Perfusion MR Parameters in Patients Screened for MR-guided High-Intensity Focused Ultrasound Ablation. Radiology, 2016, 278, 925-935.	7.3	17
56	An umbrella study of biomarker-driven targeted therapy in patients with platinum-resistant recurrent ovarian cancer: a Korean Gynecologic Oncology Group study (KGOG 3045), AMBITION. Japanese Journal of Clinical Oncology, 2019, 49, 789-792.	1.3	17
57	Chemoradiotherapy response prediction model by proteomic expressional profiling in patients with locally advanced cervical cancer. Gynecologic Oncology, 2020, 157, 437-443.	1.4	17
58	A single-arm phase II study of olaparib maintenance with pembrolizumab and bevacizumab in BRCA non-mutated patients with platinum-sensitive recurrent ovarian cancer (OPEB-01). Journal of Gynecologic Oncology, 2021, 32, e31.	2.2	17
59	Comparison of the performance of the PANArrayâ„¢ HPV test and DNA chip test for genotyping of human papillomavirus in cervical swabs. Biochip Journal, 2010, 4, 167-172.	4.9	16
60	Postoperative outcomes of MR-invisible stage IB1 cervical cancer. American Journal of Obstetrics and Gynecology, 2014, 211, 168.e1-168.e7.	1.3	16
61	Preservation of the endometrial enhancement after magnetic resonance imaging-guided high-intensity focused ultrasound ablation of submucosal uterine fibroids. European Radiology, 2017, 27, 3956-3965.	4.5	16
62	Pharmacogenomic analysis of patient-derived tumor cells in gynecologic cancers. Genome Biology, 2019, 20, 253.	8.8	16
63	Laparoendoscopic single-site (LESS) myomectomy: characteristics of the appropriate myoma. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2014, 175, 58-61.	1.1	15
64	CDK7 is a reliable prognostic factor and novel therapeutic target in epithelial ovarian cancer. Gynecologic Oncology, 2020, 156, 211-221.	1.4	15
65	A phase II study of neoadjuvant chemotherapy plus durvalumab and tremelimumab in advanced-stage ovarian cancer: a Korean Gynecologic Oncology Group Study (KGOG 3046), TRU-D. Journal of Gynecologic Oncology, 2019, 30, e112.	2.2	15
66	Recommendation guideline of Korean Society of Gynecologic Oncology and Colposcopy for quadrivalent human papillomavirus vaccine. Korean Journal of Gynecologic Oncology, 2007, 18, 259.	0.1	14
67	Squamous cell carcinoma antigen in cervical cancer and beyond. Journal of Gynecologic Oncology, 2013, 24, 291.	2.2	14
68	Timing and patterns of recurrence in epithelial ovarian cancer patients with no gross residual disease after primary debulking surgery. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2016, 56, 639-647.	1.0	14
69	Phase I Study of a B Cell-Based and Monocyte-Based Immunotherapeutic Vaccine, BVAC-C in Human Papillomavirus Type 16- or 18-Positive Recurrent Cervical Cancer. Journal of Clinical Medicine, 2020, 9, 147.	2.4	14
70	Dynamin 2 Inhibitors as Novel Therapeutic Agents Against Cervical Cancer Cells. Anticancer Research, 2016, 36, 6381-6388.	1.1	13
71	Ploidy and S-phase fraction are correlated with lymphovascular space invasion that is predictive of outcomes in endometrial cancer. International Journal of Clinical Oncology, 2012, 17, 590-597.	2.2	11
72	Borderline ovarian tumor in women aged â‰¥65 years: impact on recurrence and survival. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2015, 184, 38-42.	1.1	11

#	Article	IF	Citations
73	Time-lapse imaging of sentinel lymph node using indocyanine green with near-infrared fluorescence imaging in early endometrial cancer. Journal of Gynecologic Oncology, 2016, 27, e27.	2.2	11
74	Phase III study of cisplatin with or without S-1 in patients with stage IVB, recurrent, or persistent cervical cancer. British Journal of Cancer, 2018, 119, 530-537.	6.4	11
75	ENGOT-OV43/KEYLYNK-001: A phase III, randomized, double-blind, active- and placebo-controlled study of pembrolizumab plus chemotherapy with olaparib maintenance for first-line treatment of BRCA-nonmutated advanced epithelial ovarian cancer.. Journal of Clinical Oncology, 2019, 37, TPS5603-TPS5603.	1.6	11
76	Selected Adnexal Cystic Masses in Postmenopausal Women Can be Safely Managed by Laparoscopy. Journal of Korean Medical Science, 2005, 20, 468.	2.5	10
77	The role of appendectomy in patients with mucinous borderline ovarian tumors. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2018, 229, 112-116.	1.1	10
78	Preclinical assessment of the VEGFR inhibitor axitinib as a therapeutic agent for epithelial ovarian cancer. Scientific Reports, 2020, 10, 4904.	3.3	10
79	Comparison between laparoendoscopic single-site and conventional laparoscopic surgery in mature cystic teratoma of the ovary. Gynecology and Minimally Invasive Therapy, 2019, 8, 155.	0.9	10
80	Nomograms Predicting Platinum Sensitivity, Progression-Free Survival, and Overall Survival Using Pretreatment Complete Blood Cell Counts in Epithelial Ovarian Cancer. Cancer Research and Treatment, 2017, 49, 635-642.	3.0	10
81	Analysis of clinical outcomes of patients with adenoid cystic carcinoma of Bartholin glands. International Journal of Clinical and Experimental Pathology, 2015, 8, 5688-94.	0.5	10
82	Comparison of survival outcomes after recurrence detected by cancer antigen 125 elevation versus imaging study in epithelial ovarian cancer. Journal of Gynecologic Oncology, 2016, 27, e46.	2.2	9
83	Prognostic significance of normal-sized ovary in advanced serous epithelial ovarian cancer. Journal of Gynecologic Oncology, 2018, 29, e13.	2.2	9
84	Primary malignant melanoma of the uterine cervix treated with pembrolizumab after radical surgery: a case report and literature review. Obstetrics and Gynecology Science, 2018, 61, 524.	1.6	9
85	Pretreatment Lymph Node Metastasis as a Prognostic Significance in Cervical Cancer: Comparison between Disease Status. Cancer Research and Treatment, 2020, 52, 516-523.	3.0	9
86	Aggressive angiomyxoma of the vulva: A case report. Obstetrics and Gynecology Science, 2014, 57, 164.	1.6	9
87	Clinical characteristics and outcomes of placental site trophoblastic tumor: experience of single institution in Korea. Obstetrics and Gynecology Science, 2018, 61, 319.	1.6	8
88	Real-World Experience of Olaparib Maintenance in High-Grade Serous Recurrent Ovarian Cancer Patients with BRCA1/2 Mutation: A Korean Multicenter Study. Journal of Clinical Medicine, 2019, 8, 1920.	2.4	8
89	Optimal cutoff age for predicting prognosis associated with serous epithelial ovarian cancer: what is the best age cutoff?. Journal of Gynecologic Oncology, 2019, 30, e11.	2.2	8
90	Comparison of CA 125 alone and risk of ovarian malignancy algorithm (ROMA) in patients with adnexal mass: A multicenter study. Current Problems in Cancer, 2020, 44, 100508.	2.0	8

#	Article	IF	Citations
91	Prognostic Significance of Tumor Regression Rate during Concurrent Chemoradiotherapy in Locally Advanced Cervix Cancer: Analysis by Radiation Phase and Histologic Type. Journal of Clinical Medicine, 2020, 9, 3471.	2.4	8
92	Real-World Experience of Pembrolizumab Monotherapy in Patients with Recurrent or Persistent Cervical Cancer: A Korean Multi-Center Retrospective Study (KGOG1041). Cancers, 2020, 12, 3188.	3.7	8
93	Pazopanib (Paz) monotherapy in Asian women who have not progressed after first-line chemotherapy for advanced ovarian, Fallopian tube, or primary peritoneal carcinoma.. Journal of Clinical Oncology, 2013, 31, 5512-5512.	1.6	8
94	Maintenance olaparib after platinum-based chemotherapy in patients (pts) with newly diagnosed advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): Efficacy by surgical and tumor status in the Phase III SOLO1 trial.. Journal of Clinical Oncology, 2019, 37, 5541-5541.	1.6	8
95	Second-line olaparib maintenance therapy is associated with poor response to subsequent chemotherapy in BRCA1/2-mutated epithelial ovarian cancer: A multicentre retrospective study. Gynecologic Oncology, 2022, 165, 97-104.	1.4	8
96	Port site metastasis after robotic-assisted laparoscopic hysterectomy for uterine cervical cancer: A case report and literature review. Taiwanese Journal of Obstetrics and Gynecology, 2013, 52, 558-563.	1.3	7
97	Prevalence and oncologic outcomes of BRCA1/2 mutation and variant of unknown significance in epithelial ovarian carcinoma patients in Korea. Obstetrics and Gynecology Science, 2019, 62, 411.	1.6	7
98	Aberrant Transcript Usage Is Associated with Homologous Recombination Deficiency and Predicts Therapeutic Response. Cancer Research, 2022, 82, 142-154.	0.9	7
99	A Phase 2 Trial of Radiation Therapy With Concurrent Paclitaxel Chemotherapy After Surgery in Patients With High-Risk Endometrial Cancer: A Korean Gynecologic Oncologic GroupÂStudy. International Journal of Radiation Oncology Biology Physics, 2014, 90, 140-146.	0.8	6
100	Update of human papillomavirus vaccination. Journal of the Korean Medical Association, 2015, 58, 313.	0.3	6
101	A prospective comparative study of cosmetic satisfaction for three different surgical approaches. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2015, 190, 48-51.	1.1	6
102	Feasibility of laparoscopic cytoreduction in patients with localized recurrent epithelial ovarian cancer. Journal of Gynecologic Oncology, 2016, 27, e24.	2.2	6
103	Genomic Network-Based Analysis Reveals Pancreatic Adenocarcinoma Up-Regulating Factor-Related Prognostic Markers in Cervical Carcinoma. Frontiers in Oncology, 2018, 8, 465.	2.8	6
104	Ovarian Gynandroblastoma with a Juvenile Granulosa Cell Tumor Component in a Postmenopausal Woman. Diagnostics, 2020, 10, 537.	2.6	6
105	Anti-Cancer Activity of As4O6 and its Efficacy in a Series of Patient-Derived Xenografts for Human Cervical Cancer. Pharmaceutics, 2020, 12, 987.	4.5	6
106	A multicentre, randomised, open-label, parallel-group Phase 2b study of belotecan versus topotecan for recurrent ovarian cancer. British Journal of Cancer, 2021, 124, 375-382.	6.4	6
107	Prevalence and clinical characterization of BRCA1 and BRCA2 mutations in Korean patients with epithelial ovarian cancer. Cancer Science, 2021, 112, 5055-5067.	3.9	6
108	Combination of a pulmonary recruitment maneuver and intraperitoneal bupivacaine for the reduction of postoperative shoulder pain in gynecologic laparoscopy: a randomized, controlled trial. Obstetrics and Gynecology Science, 2020, 63, 187-194.	1.6	6

#	Article	IF	Citations
109	A single-arm, phase II study of niraparib and bevacizumab maintenance therapy in platinum-sensitive, recurrent ovarian cancer patients previously treated with a PARP inhibitor: Korean Gynecologic Oncology Group (KGOG 3056)/NIRVANA-R trial. Journal of Gynecologic Oncology, 2022, 33, .	2.2	6
110	The effect of coexisting squamous cell lesions on prognosis in patients with cervical adenocarcinoma in situ. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2015, 190, 26-30.	1.1	5
111	Prognostic factors for recurrence and survival in uterine leiomyosarcoma: Korean single center experience with 50 cases. Obstetrics and Gynecology Science, 2019, 62, 103.	1.6	5
112	Triplet chemotherapy vs doublet chemotherapy plus bevacizumab in metastatic, recurrent, and persistent cervical cancer. Current Problems in Cancer, 2020, 44, 100557.	2.0	5
113	Effect of Waiting Time from Pathological Diagnosis to Definitive Concurrent Chemoradiation for Cervical Cancer on Overall Survival. Cancer Research and Treatment, 2022, 54, 245-252.	3.0	5
114	Long-term outcomes of single-port laparoscopic myomectomy using a modified suture technique. Obstetrics and Gynecology Science, 2020, 63, 164-172.	1.6	5
115	Primary ovarian carcinoid tumor showing unusual histology and nuclear accumulation of Î²-catenin. International Journal of Clinical and Experimental Pathology, 2015, 8, 5749-52.	0.5	5
116	Is laparoendoscopic single-site surgery (LESS) retroperitoneal hysterectomy feasible?: Surgical outcomes of the initial 27 cases. Taiwanese Journal of Obstetrics and Gynecology, 2015, 54, 150-154.	1.3	4
117	Development and Validation of the Korean Version of Hand-Foot Skin Reaction and Quality of Life Questionnaire (HF-QoL-K). Journal of Korean Medical Science, 2016, 31, 1969.	2.5	4
118	Retroperitoneal Approach in Single-Port Laparoscopic Hysterectomy. Journal of the Society of Laparoendoscopic Surgeons, 2016, 20, e2016.00001.	1.1	4
119	Women with double primary cancers of the colorectum and endometrium: do they have Lynch syndrome?. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2016, 199, 208-212.	1.1	4
120	Retrospective study of combination chemotherapy with etoposide and ifosfamide in patients with heavily pretreated recurrent or persistent epithelial ovarian cancer. Obstetrics and Gynecology Science, 2018, 61, 352.	1.6	4
121	Feasibility of Single-Port Access (SPA) Laparoscopy for Large Ovarian Tumor Suspected to Be Borderline Ovarian Tumor. Frontiers in Oncology, 2020, 10, 583515.	2.8	4
122	Comparison of Laparoscopy and Laparotomy for Para-Aortic Lymphadenectomy in Women With Presumed Stage Iâ€“II High-Risk Endometrial Cancer. Frontiers in Oncology, 2020, 10, 451.	2.8	4
123	Metabolic syndrome and persistent cervical human papillomavirus infection. Gynecologic Oncology, 2021, 161, 559-564.	1.4	4
124	Laparoendoscopic single-site radical hysterectomy for early stage cervical cancer. Obstetrics and Gynecology Science, 2017, 60, 110.	1.6	3
125	Significance of serum CA125 level in surgically resected cervical adenocarcinoma with adverse features. Journal of Gynecologic Oncology, 2021, 32, e72.	2.2	3
126	Efficacy of maintenance olaparib for newly diagnosed, advanced ovarian cancer patients (pts) by BRCA1 or BRCA2 mutation in the phase III SOLO1 trial.. Journal of Clinical Oncology, 2019, 37, 5551-5551.	1.6	3

#	Article	IF	Citations
127	Cost-Utility of a Two-Dose Human Papillomavirus Vaccination Programme Added to Cervical Cancer Screening Compared with Cervical Cancer Screening Alone in Korea. Asian Pacific Journal of Cancer Prevention, 2019, 20, 425-435.	1.2	3
128	Molecular Signature for Lymphatic Invasion Associated with Survival of Epithelial Ovarian Cancer. Cancer Research and Treatment, 2018, 50, 461-473.	3.0	3
129	Decidualization of intranodal endometriosis in a postmenopausal woman. International Journal of Clinical and Experimental Pathology, 2015, 8, 1025-30.	0.5	3
130	Mesothelial cell inclusions in pelvic and para-aortic lymph nodes: a clinicopathologic analysis. International Journal of Clinical and Experimental Pathology, 2015, 8, 5318-26.	0.5	3
131	Clinical outcome of pulmonary lymphangitic carcinomatosis in gynecologic malignancy: A single-institution experience. Taiwanese Journal of Obstetrics and Gynecology, 2022, 61, 333-338.	1.3	3
132	Prognostic Significance of HER3 Expression in Patients with Cervical Cancer. Cancers, 2022, 14, 2139.	3.7	3
133	Phase II Study of Combination Chemotherapy with Etoposide and Ifosfamide in Patients with Heavily Pretreated Recurrent or Persistent Epithelial Ovarian Cancer. Journal of Korean Medical Science, 2009, 24, 945.	2.5	2
134	Endometrial cancer six years after colon cancer in Lynch syndrome: Single institution case in Korea. Korean Journal of Obstetrics & Gynecology, 2012, 55, 870.	0.1	2
135	Robotic high para-aortic lymph node dissection with high port placement using same port for pelvic surgery in gynecologic cancer patients. Journal of Gynecologic Oncology, 2015, 26, 222.	2.2	2
136	Catamenial hemoptysis accompanied by subcutaneous endometriosis treated with combination therapy. Obstetrics and Gynecology Science, 2017, 60, 236.	1.6	2
137	Identification of Candidate Genes Associated with Susceptibility to Ovarian Clear Cell Adenocarcinoma Using cis-eQTL Analysis. Journal of Clinical Medicine, 2020, 9, 1137.	2.4	2
138	Minimally-Invasive Versus Abdominal Hysterectomy for Endometrial Carcinoma With Glandular or Stromal Invasion of Cervix. Frontiers in Oncology, 2021, 11, 670214.	2.8	2
139	An umbrella study of biomarker-driven targeted therapy in patients with platinum-resistant recurrent ovarian cancer (KGOG 3045, AMBITION).. Journal of Clinical Oncology, 2021, 39, 5520-5520.	1.6	2
140	Phase IIa study of BVAC-C in HPV type 16 or 18 positive recurrent cervical carcinoma.. Journal of Clinical Oncology, 2021, 39, 5512-5512.	1.6	2
141	Early Metabolic Response Assessed Using 18F-FDG-PET/CT for Image-Guided Intracavitary Brachytherapy Can Better Predict Treatment Outcomes in Patients with Cervical Cancer. Cancer Research and Treatment, 2021, 53, 803-812.	3.0	2
142	Validation of Potential Protein Markers Predicting Chemoradioresistance in Early Cervical Cancer by Immunohistochemistry. Frontiers in Oncology, 2021, 11, 665595.	2.8	2
143	Prognostic Relevance of BRCA1 Expression in Survival of Patients With Cervical Cancer. Frontiers in Oncology, 2021, 11, 770103.	2.8	2
144	Impact of no residual disease on postoperative computed tomography on survival in patients with optimally debulked advanced high-grade serous ovarian cancer during upfront surgery. Gynecologic Oncology, 2022, , .	1.4	2

#	Article	IF	Citations
145	A rare case of primary ovarian leiomyoma with atypical Meigs' syndrome. Korean Journal of Obstetrics & Gynecology, 2012, 55, 285.	0.1	1
146	Vaginal cancer with multiple liver and pulmonary metastases that achieved long-term survival. Obstetrics and Gynecology Science, 2013, 56, 416.	1.6	1
147	Single-port access (SPA) laparoscopic myomectomy with uterine artery ligation via a retroperitoneal approach is feasible in women with large uterine leiomyoma. Taiwanese Journal of Obstetrics and Gynecology, 2021, 60, 752-757.	1.3	1
148	Frequent use of complex surgeries and survival outcomes in ovarian cancer patients: A propensity score analysis from the Korean Gynecologic Oncology Group.. Journal of Clinical Oncology, 2014, 32, 5537-5537.	1.6	1
149	Randomized phase III trial of carboplatin/paclitaxel alone (CP) or in combination with bevacizumab followed by bevacizumab (CPB) and secondary cytoreduction surgery in platinum-sensitive recurrent ovarian cancer: GOG0213, an NRG Oncology/GOG Studyâ€"Analysis of patient reported outcomes (PRO) on chemotherapy randomization.. Journal of Clinical Oncology, 2015, 33, 5525-5525.	1.6	1
150	Expressions of Tight Junction Protein Claudin-1 and Claudin-7 in Squamous Cell Carcinoma of the Uterine Cervix. Korean Journal of Physiology, 2004, 15, 41.	0.0	1
151	A case of primitive neuroectodermal tumor of the ovary. Korean Journal of Obstetrics & Gynecology, 2012, 55, 777.	0.1	1
152	Interim analysis from a phase II study of olaparib maintenance with pembrolizumab and bevacizumab in BRCA non-mutated patients with platinum-sensitive recurrent ovarian cancer: APGOT-ov4/OPEB-01.. Journal of Clinical Oncology, 2022, 40, e17579-e17579.	1.6	1
153	Effective thermal destruction of residual tubal epithelium using an advanced sealing device in opportunistic salpingectomy: A randomized trial. Gynecology and Minimally Invasive Therapy, 2017, 6, 108-112.	0.9	0
154	Real-world Experience of Niraparib in Newly-diagnosed Epithelial Ovarian Cancer. Anticancer Research, 2021, 41, 4603-4607.	1.1	0
155	Neoadjuvant chemotherapy with mitomycin-C, vincristine and cisplatin (MVC) for patients with loco-regionally advanced cervical carcinoma. Korean Journal of Gynecologic Oncology, 2006, 17, 15.	0.1	0
156	Superior vena cava syndrome secondary to hickman catheter in the advanced cervical cancer patient treated with concurrent chemoradiotherapy: A case report. Korean Journal of Obstetrics & Gynecology, 2012, 55, 761.	0.1	0
157	Reply: Hereditary portion as an initial genetic approach in gynecologic cancer: synchronous tumor of ovary and endometrium. Journal of Gynecologic Oncology, 2012, 23, 73.	2.2	0
158	An open label, randomized, parallel, phase II trial to evaluate the efficacy and safety of cremophor-free, polymeric micelle formulation of paclitaxel compared to paclitaxel in subjects with ovarian cancer.. Journal of Clinical Oncology, 2013, 31, 5568-5568.	1.6	0
159	Propensity-score analysis of neoadjuvant chemotherapy vs. primary surgery in advanced ovarian cancer: Does surgical quality matter?. Journal of Clinical Oncology, 2015, 33, 5568-5568.	1.6	0
160	Efficacy and safety comparison between belotecan and topotecan in patients with recurrent or refractory ovarian cancer: A multi-center, randomized, open-labelled, parallel-group phase IIb trial.. Journal of Clinical Oncology, 2015, 33, 5527-5527.	1.6	0
161	Prognostic model for disease-free survival, lymphatic and/or hematogenous recurrence, in patients with early stage cervical cancer treated with radical hysterectomy: A Korean Gynecologic Oncology Group Study.. Journal of Clinical Oncology, 2016, 34, e17000-e17000.	1.6	0
162	Quality of life (QoL) in a phase III trial of pelvic external beam radiation therapy (PXRT) versus vaginal cuff brachytherapy followed by paclitaxel/carboplatin chemotherapy (VCB/C) in patients with high risk, early stage endometrial carcinoma: An NRG Oncology/Gynecologic Oncology Group study.. Journal of Clinical Oncology, 2018, 36, 5593-5593.	1.6	0

#	Article	IF	Citations
163	Survival Effects of Cytoreductive Surgery for Refractory Patients after Neoadjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer. Yonsei Medical Journal, 2020, 61, 935.	2.2	0
164	A single-arm, phase II study of niraparib and bevacizumab maintenance therapy in patients with platinum-sensitive, recurrent ovarian cancer previously treated with a PARP inhibitor: Korean Gynecologic Oncology Group (KGOG 3056)/NIRVANA-R trial.. Journal of Clinical Oncology, 2022, 40, TPS5610-TPS5610.	1.6	0